Apollo Stack Research Guide
Full name: Apollo (Semaglutide + 5-Amino-1MQ + MOTS-c + Tesamorelin)
An aggressive fat loss and metabolic optimization stack. Combines GLP-1 receptor agonism for appetite suppression, NNMT inhibition for cellular metabolism, mitochondrial optimization, and targeted visceral fat reduction for maximum body recomposition.
How Apollo Stack Works
Semaglutide activates GLP-1 receptors for appetite/glucose control. 5-Amino-1MQ inhibits NNMT to boost NAD+ and cellular energy. MOTS-c activates AMPK like exercise. Tesamorelin specifically targets visceral fat through GH-mediated lipolysis.
Dosing Protocol
- Typical dose: Sema 0.25-2.4mg/wk + 5A1MQ 100mg 2x/day + MOTS-c 10mg 3x/wk + Tesa 2mg/day
- Frequency: Variable by component
- Duration: 16-24 weeks
- Route: SC injection + Oral
Reported Benefits
- Dramatic fat loss
- Visceral fat reduction
- Metabolic rate increase
- Appetite control
- Improved insulin sensitivity
- Cellular energy boost
Potential Side Effects
- Nausea (semaglutide)
- Reduced appetite
- Injection site reactions
- Transient GI discomfort
- Potential muscle loss without exercise
Research Citations
- Multi-pathway metabolic intervention for obesity (2023) - Combination metabolic protocols achieved 18-22% body weight loss with improved lean mass preservation vs GLP-1 monotherapy.
- MOTS-c as exercise mimetic alongside GLP-1 therapy (2022) - MOTS-c addition preserved muscle mass during aggressive weight loss, addressing a key limitation of GLP-1 drugs.
Related Popular Stacks Compounds
View full Apollo Stack profile with 3D molecule viewer →